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Patient Demographics and Reported Outcomes in Funded versus Non-funded Studies 
Assessing Thromboprophylaxis after Total Joint Arthroplasty: A Systematic Review
There are numerous studies discussing thromboprophylaxis after total joint arthroplasty
(TJA), which have varying conclusions. The patient inclusion criteria may be different for
each study, which may lead to selection bias and misrepresenting data.
The purpose of this study was to investigate if industry funding impacted patient
demographics and overall reported outcomes of studies analyzing venous thromboembolism
(VTE) prevention after TJA.
There were 57 studies included in this systematic review; 29 studies were industry
funded and 28 were non-funded
• There was no overall drug effect between reporting outcomes, patient
demographics, and level of funding.
• There were no significant differences between patient age, BMI, or revision
exclusions between funded and non-funded studies.
• However, funded studies reported less pulmonary embolisms (PE) (0.29%,
95% CI 0.19-0.42) compared to non-funded studies (0.72%, 95% CI; 0.47-1.12)
(p=0.001).
• Funded studies also reported fewer events of major bleeding (0.75%, 95% CI;
0.52-1.11) than non-funded studies (1.4%, 95% CI; 0.84-2.33) (p=0.046).
• Funded studies also reported significantly less 90-day mortality (0.12% (95%
CI; 0.09-0.16) than non-funded studies (0.38%, 95% CI; 0.25-0.57) (p=0.000).
Electronic searches were completed for Ovid, PubMed, and Embase. Studies were included if:
(1) published in the English language between 2000 and 2016
(2) including patients undergoing total hip arthroplasty (THA) or total knee arthroplasty
(TKA)
(3) evaluating prevention and control of postoperative VTE with at least one of the
following thromboprophylactic agents: aspirin, enoxaparin, deltaparin, dabigatran,
apixaban, rivaroxaban, dabigatran, ximelagatran, fondaparinux or coumadin. Data was
extracted and analyzed via mixed-effect logistic regression.
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TABLES 1-3 RESULTS
MATERIALS & METHODS
DISCUSSION
Industry-funded studies reported less PE, major bleeding, and mortality compared
to non-funded studies. There were no differences in patient demographics or drug
effect.
It is important to investigate the underlining reason how funded studies are reporting
fewer poor outcomes than non-funded studies. In addition, our data suggests careful
examination of data from funded studies when applying results to a clinical basis.
Future studies should further investigate patient demographics, study design, and
additional forms of bias that may arise in orthopedic research.
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Funded Studies 
(n=29)
Non-funded Studies 
(n=28) p-value
Conflict of Interest 23 9 0.000
Excluded Revisions 15 12 0.512
Retrospective 4 14 0.013
Male (%) 39.41% 31.09% 0.019
Age (mean) 66.7 66.7 1.000
BMI (mean) 29.0 28.8 0.729
Table 1. Patient Demographics and study information of funded vs. non-funded studies. 
Funded Studies Non-funded Studies p-value
PE % (95% CI) 0.29% (0.19 - 0.42) 0.72% (0.47 - 1.12) 0.001
DVT % (95% CI) 3.78% (2.09 - 6.72) 3.27% (1.84-5.73) 0.728
Major Bleeding % (95% 
CI) 0.75% (0.52 - 1.11) 1.4% (0.84 - 2.33) 0.046
Mortality % (95% CI) 0.12% (0.09 - 0.16) 0.38% (0.25 -0 .57) 0.000
Table 3. Outcomes of funded vs. non-funded studies.
Funded 
Studies
Non-funded 
Studies
Aspirin +/- foot 
pump 4 8
Enoxaparin 18 18
Foot pump only 1 3
Oral 
anticoagulants* 20 11
Other LMWH& 5 6
Warfarin 7 9
Table 2. Number of funded and non-funded studies including each drug category.
Records identified 
by electronic 
literature search
(n=995)
Records after 
duplicates 
removed (n=766)
Records screened 
(n=766)
Figure 1. Screening and selection for this systematic review.
Full Texts 
assessed for 
eligibility 
(n=105)
Studies included 
in analysis (n=57)
Records excluded after 
screening titles and 
abstracts (n=661)
Full Texts excluded (n=48)
-No sole chemoprophylactic agent (n=20)
-Not original studies (n=10)
-Not available in full texts (n=3)
-Did not report patient demographics (n=8)
-Did not report adverse outcomes (n=7)
*: İncluding dabigatran, apixaban, rivaroxaban, ximelgatran. 
&: İncluding fondaparinux and daltaparin.
